BSE · 512101
Triochem Products Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1 Cr with net profit ₹8 Cr — a 922% net margin, versus -38.12% the period before.
Shareholding
As of 2026-06-30
- Promoter68.65%
- Public31.35%
55 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #95 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,516 Cr | 35.34 | 5.34 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,501 Cr | 22.84 | 4.11 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,943 Cr | 31 | 3.22 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,091 Cr | 96.1 | 19.83 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹95,996 Cr | 25.39 | 2.53 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,404 Cr | 29.61 | 2.51 | 11.07% | 9.73% |
| Lupin Limited | ₹95,011 Cr | 15.95 | 4.23 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,456 Cr | 43.34 | 5.67 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,157 Cr | 21.84 | 6.48 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,558 Cr | 87.05 | 1.84 | 1.14% | 2.89% |
| Triochem Products Ltd.(this company) | ₹0 Cr | — | 0.02 | -3.14% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashTriochem Products Ltd. is listed on the Indian markets. The company reported a revenue of Rs 1.05 Cr and a profit margin of 0% for the most recent period. Its book value is Rs 842.65.
Positives
- +The debt-to-equity ratio is 0.00, indicating no debt.
- +Promoter shareholding is substantial at 68.65% as on June 30, 2026.
- +There are no pledged shares by the promoters.
Negatives
- −Revenue has significantly declined to Rs 1.05 Cr in Mar 2025 from Rs 14.07 Cr in Mar 2021.
- −The company has reported negative Net Profit for Mar 2025 at -Rs 0.40 Cr.
- −Return on Equity (ROE) is significantly negative at -314.1%.
- −Return on Capital Employed (ROCE) is negative at -2.76%.
- −Quarterly results have consistently shown zero revenue since Dec 2024.
Financial performance
Triochem Products Ltd. reported a revenue of Rs 1.05 Cr for Mar 2025. This marks a decline from its revenue of Rs 14.07 Cr in Mar 2021. The company's net profit was -Rs 0.40 Cr in Mar 2025, following a net profit of Rs 1.32 Cr in Mar 2022. The Earnings Per Share (EPS) for Mar 2025 was -Rs 16.33.
Profitability & returns
The company's Return on Equity (ROE) is -314.1%, and its Return on Capital Employed (ROCE) is -2.76%. For Mar 2025, the profit margin was 0%. EBITDA for Mar 2025 was -Rs 0.25 Cr, a decrease from Rs 1.78 Cr in Mar 2022.
Balance sheet
Triochem Products Ltd. has a debt-to-equity ratio of 0.00, indicating no debt. The book value per share stands at Rs 842.65. No market capitalization figure is available for the company.
Ownership & pledges
Public shareholding is 31.35%, distributed among 55 shareholders. There are no shares pledged by the promoters.
Data as of — price: 2026-09-10 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.